Cancer Support Community’s New Short Documentary Film Named Official Selection at CINEHEALTH International Health and Wellness Film and Video Festival
August 30, 2023 11:17 ET
|
Cancer Support Community
Washington D.C., Aug. 30, 2023 (GLOBE NEWSWIRE) -- The Cancer Support Community (CSC), a nonprofit organization dedicated to uplifting and strengthening all people impacted by cancer by providing...
Syapse and Pierian Announce Genomics Collaboration to Power Precision Oncology
June 14, 2022 10:00 ET
|
Syapse
SAN FRANCISCO, June 14, 2022 (GLOBE NEWSWIRE) -- Syapse®, a leading real-world evidence company announced with Pierian®, a global leader in advanced clinical genomics technology, a new joint...
Axim® Biotechnologies Announces Positive Results From Stability And Dissolution Tests On Medchew Rx Showing Greater Than 90% Availability
August 07, 2018 08:55 ET
|
AXIM BIOTECHNOLOGIES, INC
NEW YORK, Aug. 07, 2018 (GLOBE NEWSWIRE) -- AXIM® Biotechnologies, Inc. (AXIM® Biotech) (OTC: AXIM), a world leader in cannabinoid research and development, today announced positive results from...
AXIM Biotech Announces Successful Completion of Exploratory Meeting with the Dutch Medicines Evaluation Board on MedChew Rx Program for Treatment of Pain and Spasticity in MS Patients
January 23, 2018 09:00 ET
|
AXIM BIOTECHNOLOGIES, INC
NEW YORK, Jan. 23, 2018 (GLOBE NEWSWIRE) -- AXIM® Biotechnologies, Inc. (OTC:AXIM), the world leader in cannabinoid research and development, announced today that it has successfully completed an...
Axim Biotechnologies Announces Phase IIa Trial Results Validating its Proprietary Cannabinoid Delivery Method for Treatment of Irritable Bowel Syndrome (IBS)
November 21, 2017 09:00 ET
|
AXIM BIOTECHNOLOGIES, INC
NEW YORK, Nov. 21, 2017 (GLOBE NEWSWIRE) -- AXIM® Biotechnologies, Inc. (AXIM® Biotech) (OTC:AXIM), a world leader in cannabinoid research and development, today announced clinical trial results...
New U.S. Patent Allowance Granted to AXIM® Biotechnologies, Inc. for Cannabinoid Ophthalmic Solutions for Glaucoma and Conjunctivitis Treatment
October 05, 2017 09:00 ET
|
AXIM Biotechnologies, Inc
NEW YORK, Oct. 05, 2017 (GLOBE NEWSWIRE) -- AXIM® Biotechnologies, Inc. (AXIM® Biotech), (OTC:AXIM), a world leader in cannabinoid research and development, today announced that the United States...
AXIM Biotech to Present at Rodman & Renshaw 19th Annual Global Investment Conference in New York City
September 07, 2017 09:00 ET
|
AXIM Biotechnologies, Inc
NEW YORK, Sept. 07, 2017 (GLOBE NEWSWIRE) -- AXIM Biotechnologies, Inc. (AXIM Biotech) (OTC:AXIM), a world leader in cannabinoid research and development, today announced that the Company will be...
AXIM Biotechnologies Reports Second Quarter 2017 Results
August 22, 2017 09:00 ET
|
AXIM Biotechnologies, Inc
NEW YORK, Aug. 22, 2017 (GLOBE NEWSWIRE) -- AXIM® Biotechnologies, Inc. (AXIM® Biotech) (OTC:AXIM), a world leader in cannabinoid research and development, today announced results for the quarter...
AXIM Biotech Enters Services Agreement With Israel-Based CRO to Begin Clinical POC Study on CBD and Gabapentin Chewing Gum for Treatment of Restless Leg Syndrome
July 20, 2017 09:00 ET
|
AXIM Biotechnologies, Inc
NEW YORK, July 20, 2017 (GLOBE NEWSWIRE) -- AXIM Biotechnologies, Inc. (AXIM Biotech) (OTC:AXIM), a world leader in cannabinoid research and development, today announced that it has entered into a...
AXIM® Biotech Enters IBS Clinical Trial for CanChew CBD Chewing Gum
January 18, 2017 09:00 ET
|
AXIM Biotechnologies, Inc
NEW YORK, Jan. 18, 2017 (GLOBE NEWSWIRE) -- AXIM® Biotechnologies, Inc. (AXIM® Biotech) (OTC:AXIM), a world leader in cannabinoid research and development, entered a clinical trial on treating...